Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting

Magnetic Resonance in Medicine

Volumn 60, Issue 6, 2008, Pages 1337-1346

  Corot, Claire ^a   Robert, Philippe ^a   Lancelot, Eric ^a   Prigent, Philippe ^a   Ballet, Sébastien ^a   Guilbert, Irène ^a   Raynaud, Jean Sébastien ^a   Raynal, Isabelle ^a   Port, Marc ^a  

^a Laboratoire Guerbet   (France)

Author keywords

Folate; Folate receptor; High relaxivity gadolinium chelates; Molecular imaging; MRI; Tumor

Indexed keywords

BINDING ENERGY; CHELATION; GADOLINIUM; MAGNETIC RESONANCE IMAGING; MAMMALS; TUMORS;

BINDING AFFINITIES; DYNAMIC CONTRAST ENHANCED MRIS (DCE); FOLATE; FOLATE RECEPTOR; GADOLINIUM CHELATES; POTENTIAL CAPACITY; REFERENCE COMPOUNDS; SIGNAL ENHANCEMENT;

MOLECULAR IMAGING;

CONTRAST MEDIUM; FOLATE RECEPTOR; GADOLINIUM CHELATE; P866; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; SENSITIVITY ANALYSIS; TUMOR; TUMOR CELL;

EID: 57149104739     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21773     Document Type: Article

References (36)

1. Antony AC. The biological chemistry of folate receptors. Blood 1992;79:2807-2820.
2. Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 2004;56:1099-1109.
3. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067-1084.
4. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharmaceut Sci 2005;94:2135-2146.
5. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-2443.
6. Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, Burt RW, Ellis PR, Mathias CJ, Green MA, Gershenson DM. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44:700-707.
7. Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004;45:857-866.
8. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol 1997;32:748-754.
9. Konda SD, Aref M, Brechbiel M, Wiener EC. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. Invest Radiol 2000;35:50-57.
10. Konda SD, Wang S, Brechbiel M, Wiener EC. Biodistribution of a 153 Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest Radiol 2002;37:199-204.
11. Corot C, Robert P, Lancelot E, Prigent P, Port M. Tumor imaging using a high relaxivity gadolinium chelate targeted to the folate receptor. In: Proceedings of the 13th Annual Meeting of ISMRM, Miami Beach, FL, USA, 2005 (Abstract 2601).
12. Swanson SD, Kukowska-Latallo JF, Patri AK, Baker Jr JR. Targeted contrast using gadolinium labelled G5 dendrimers. In: Proceedings of the 14th Annual Meeting of ISMRM, Seattle, WA, USA, 2006 (Abstract 1830).
13. Kalber TI, Karnaly N, Hussein MO, Jorgensen MR, Su PW, Bel JD, Miller AD. A novel low molecular weight folate receptor targeted contrast agent for magnetic resonance tumor imaging. In: Proceedings of the 15th Annual Meeting of ISMRM, Berlin, Germany, 2007 (Abstract 1156).
14. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004;11:996-1004.
15. Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, Hoebeke J, Duguet E, Colombo P, Couvreur P. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chem 2005;16:1181-1188.
16. Oyewumi MO, Mumper RJ. Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjugate Chem 2002;13:1328-1335.
17. Zhou R, Choi H, Corbin I, Choi S, Li H, Gray B, Glickson JD, Chen I-W, Kung H. MR imaging of low density lipoprotein and folate receptors. In: Proceedings of the 12th Annual Meeting of ISMRM, Kyoto, Japan, 2004 (Abstract 286).
18. Kamaly N, Kalber TL, Thanou M, So PW, Bell JD, Miller AD. Folate targeted paramagnetic liposomes for magnetic resonance tumour imaging. In: Proceedings of the 15th Annual Meeting of ISMRM, Berlin, Germany, 2007 (Abstract 1157).
19. Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. Ligand binding and kinetics of folate receptor recycling in vivo: impact of receptor mediated drug delivery. Mol Pharmacol 2004;66:1406-1414.
20. Luo J, Smith MD, Lantrip DA, Wang S, Fuchs PL. Efficient synthesis of pyrofolic acid and pteroyl azide reagents for the production of carboxyl-differentiated derivatives of folic acid. J Am Chem Soc 1997;119:10004-10013.
21. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.
22. Ke CY, Mathias C, Green MA. Folate-receptor-targeted radionuclide imaging agents. Adv Drug Deliv Rev 2004;56:1143-1160.
23. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR, Banaszak Holl MM. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 2007;14:107-115.
24. Stella B, Arpicco S, Peracchia T, Desmaelle D, Hoebeke J, Renoir M, D'Angelo J, Cattel L, Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J Pharmaceut Sci 2000;89:1452-1464.
25. Bettio A, Honer M, Muller C, Bruhlmeier, Muller U, Schibli R, Groehn V, Schubiger P, Ametamey S. Synthesis and preclinical evaluation of a folic acid derivative labelled with 18F for PET imaging of folate receptor-positive tumors. J Nucl Med 2006; 47:1153-1160.
26. Muller C, Schubiger PA, Schibli R. Synthesis and in vitro/in vivo evaluation of novel 99mTc(CO)3-folates. Bioconjugate Chem 2006; 17: 797-806.
27. Corzo J. Time, the forgotten dimension of ligand binding teaching. Biochem Mol Biol Educ 2006;34:413-416.
28. Leamon CP, Parker MA, Vlahov IR, Xu LC, Reddy JA, Vetzel M, Douglas N. Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug Chem 2002;13:1200-1210.
29. Crich S, Biancone L, Cantaluppi V, Duo D, Esposito G, Russo S, Camussi G, Aime S. Improved route for the visualization of stem cells labelled with a Gd-/Eu-chelate as dual (MRI and fluorescence) Agent. Magn Reson Med 2004;51:938-944.
30. Terreno E, Crich SG, Belfiore S, Biancone L, Cabella C, Esposito G, Manazza A, Aime S. Effect of the intracellular localization of a Gd-based imaging probe on the relaxation enhancement of water protons. Magn Reson Med 2006;55:491-497.
31. Muller C, Dumas C, Hoffmann U, Schubiger PA, Schibli R. Organonmetallic 99mTc-technicium(I)- and Re-rhenium(I)-folate derivatives for potential use in nuclear medicine. J Organomet Chem 2004;689:4712-4721.
32. Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS, Green MA. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med 1998;39:1579-1585.
33. Seevinck PR, Seppenwoolde JH, De Wilt TC, Nijsen FW, Beekman FJ, Van Het Schip AD, Bakker CJG. Factors affecting the sensitivity and detection limits of MRI, CT and SPECT for multimodal diagnostic and therapeutic agents. Anticancer Agents Med Chem 2007;7:317-334.
34. Rossin R, Pan D, Qi K, Turner JL, Sun X, Wooley KL, Welch MJ. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 2005;46:1210-1218.
35. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004;56:1205-1217.
36. Saborowski O, Simon GH, Raatschen HJ, Wendland MF, Fu Y, Henning T, Baehner R, Corot C, Chen MH, Daldrup-Link HE. MR imaging of antigen-induced arthritis with a new, folate receptor-targeted contrast agent. Contrast Media Mol Imaging 2007;2:72-81.